Comments
Zydus Cadila has received final approval from the US health regulator to market Diclofenac Sodium Topical Solution, used for treating signs and symptoms of osteoarthritis of the knees, said Cadila Healthcare in a notice to the stock exchanges. It is a non-steroidal anti-inflammatory drug. The drug will be produced at the group’s topical manufacturing facility at Ahmedabad, the company added. The Zydus group has more than 185 approvals, and has, so far, filed over 320 abbreviated new drug applications (ANDAs) since it started filings in 2003-04. Shares of Cadila Healthcare closed 0.66 per cent higher at ₹387.65 on the NSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.